Not meaning to wade into someone else's debate. But does the content of the interim results for Travere's Phase 3 FSGS trial for Sparsentan shed a bit more light on this discussion. I'm expecting something similar from DXB in mid-March. This was almost an identical interim milestone which had a specific proteinuria endpoint and references statistical significance.
Link to their interim results announcement - here
Ann: Application for quotation of securities - DXB, page-112
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.0¢ |
Change
0.020(3.92%) |
Mkt cap ! $291.6M | |||
| Open | High | Low | Value | Volume |
| 51.0¢ | 53.8¢ | 51.0¢ | $782.0K | 1.490M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6408 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 35657 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |